Xi Chen is the founder of RootPath Genomics. RootPath Genomics has raised $7M in total funding. Latest round: Seed. Based in Cambridge, USA.
Xi Chen is the CEO of RootPath Genomics, a Cambridge-based biotechnology company that develops a personalized T cell therapy platform for cancer immunotherapy. The company raised a $7 million seed funding round in August 2018. Chen is one of the founders, who are scientists and bioengineers with expertise in synthetic biology, gene editing, and single-cell sequencing technologies. RootPath aims to advance immuno-oncology programs and obtain key data on accuracy, efficacy, and safety in animal models.
Full founder directory · Investor directory · Company funding database · Fundraising library